NOD2 gene variants are a risk factor for culture-positive spontaneous bacterial peritonitis and monomicrobial

Tony Bruns1, Jack Peter, Philipp A Reuken

  • 1Department of Internal Medicine II, Division of Gastroenterology, Hepatology, and Infectious Diseases, Jena University Hospital, Jena, Germany. t.bruns@bham.ac.uk

Abstract

Insights

Genetic variants in the NOD2 gene increase the risk of developing spontaneous bacterial peritonitis (SBP) and bacterascites in patients with cirrhosis. These NOD2 variants may also impact patient survival.

Area of Science:

  • Gastroenterology
  • Genetics
  • Infectious Diseases

Background:

  • Spontaneous bacterial peritonitis (SBP) is a serious complication in patients with decompensated cirrhosis.
  • Bacterial translocation from the gut is a key mechanism in SBP development.
  • NOD2 gene variants have been implicated in bacterial translocation and SBP risk.

Purpose of the Study:

  • To investigate the association between common NOD2 variants and the risk of SBP in patients with decompensated cirrhosis.
  • To determine if NOD2 variants are independent predictors of ascitic fluid infection and survival.

Main Methods:

  • Genotyping of common NOD2 variants (R702W, G908R, 1007fs) using TaqMan polymerase chain reaction.
  • Analysis of ascitic fluid neutrophil count and bacterial culture results in 175 patients with decompensated cirrhosis.
  • Logistic regression analysis to identify predictors of infection and survival.

Main Results:

  • Patients with SBP, culture-positive SBP, and bacterascites were more likely to carry NOD2 variants.
  • Specific NOD2 mutations (1007fs, G908R) were associated with culture-positive SBP, and R702W with bacterascites.
  • NOD2 variants, higher MELD score, and prior SBP were independent predictors of ascitic fluid infection.
  • NOD2 variants were associated with survival in patients without hepatocellular carcinoma.

Conclusions:

  • NOD2 variants are associated with an increased risk of culture-positive SBP and bacterascites in cirrhosis patients.
  • NOD2 variants may serve as independent predictors for ascitic fluid infection and influence patient survival.
  • Further research into NOD2's role in SBP pathogenesis and management is warranted.

Related Concept Videos

Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Comparing Copy Number Variations and SNPs02:26

Comparing Copy Number Variations and SNPs

Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...